FOLFOX
|
WikiDoc Resources for FOLFOX |
|
Articles |
|---|
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FOLFOX at Clinical Trials.gov Clinical Trials on FOLFOX at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FOLFOX
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating FOLFOX Risk calculators and risk factors for FOLFOX
|
|
Healthcare Provider Resources |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs
- FOL– Folinic acid (leucovorin)
- F – Fluorouracil (5-FU)
- OX – Oxaliplatin (Eloxatin)[1]
FOLFOX4
Adjuvant treatment in patients with stage III colon cancer is recommended for 12 cycles, every 2 weeks. The recommended dose schedule given every two weeks is as follows:
Day 1: Eloxatin® 85 mg/m² IV infusion in 250-500 mL D5W and leucovorin 200 mg/m² IV infusion in D5W both given over 120 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m² IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.
Day 2: Leucovorin 200 mg/m² IV infusion over 120 minutes, followed by 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m² IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.
| FOLFOX4 | ||||
|---|---|---|---|---|
| drug | dose | administration | time | term |
| Oxaliplatin | 85 mg/m² | IV infusion | 2 h | day 1 |
| Folinic acid | 200 mg/m² | IV infusion | 2 h | day 1 + 2 |
| Fluorouracil | 400 mg/m² | IV bolus | 2 min | day 1 + 2 |
| Fluorouracil | 600 mg/m² | IV infusion | 22 h | day 1 + 2 |
Premedication with antiemetics, including 5-HT3 blockers with or without dexamethasone, is recommended.
References
- ↑ Cancer Research UK, CancerHelp UK
- ↑ de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000). "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer". J Clin Oncol. 18 (16): 2938–47. PMID 10944126. HTML PDFPatients with advanced colorectal cancer were given 5-fluorouracil and leukovorin. Those who were also given oxaliplatin were more likely to have a response, and had longer progression-free survival, than patients without oxaliplatin. However, patients with oxaliplatin didn't survive any longer than patients without it.
- ↑ FDA Approval: Eloxatin [oxaliplatin] PDF
- Goldberg R, Sargent D, Morton R, Fuchs C, Ramanathan R, Williamson S, Findlay B, Pitot H, Alberts S (2004). "A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer". J Clin Oncol. 22 (1): 23–30. PMID 14665611.